Target intelligence / Profile preview

65 kDa phosphoprotein (pp65)

Target
pp65
Molecular classification
Viral protein, Phosphoprotein, Other
01

Overview

The 65 kDa phosphoprotein (pp65), encoded by the UL83 gene of human cytomegalovirus (HCMV), is the most abundant tegument protein and a major structural component of mature viral particles. It plays a critical role in viral pathogenesis by modulating the host's immune system, specifically by counteracting the host antiviral response through the inhibition of interferon regulatory factor 3 (IRF3) nuclear translocation and the inactivation of the DNA sensor cGAS. Additionally, pp65 is involved in the transactivation of viral immediate-early genes and the proper assembly of viral particles. Because pp65 is highly immunodominant and frequently expressed in certain malignancies like glioblastoma and medulloblastoma, it has become a prominent therapeutic target.

Therapeutic strategies targeting pp65 include peptide-based vaccines, mRNA-loaded dendritic cell vaccines, and enveloped virus-like particles, which aim to stimulate a robust host T-cell-mediated immune response against CMV-infected or tumor cells. Adoptive cell therapies utilizing ex vivo expanded CMV-specific cytotoxic T lymphocytes (CTLs) are also being developed to treat CMV infections in immunocompromised transplant recipients. While targeting pp65 is highly promising for both infectious diseases and oncology, challenges include ensuring complete protection when targeted alone and managing potential immune-related adverse events.

Other names
65 kDa matrix phosphoproteinPhosphoprotein UL83Tegument protein UL83Tegument protein pp65Cytomegalovirus antigen pp65CMV pp65UL83
02

Mechanism of action

Active immunotherapy (vaccines) designed to stimulate host helper and cytotoxic T-lymphocyte (CTL) responses against pp65-expressing cells, or adoptive cell therapy using ex vivo expanded CMV-specific T cells to target and destroy infected or tumor cells presenting pp65 epitopes.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionCancer
05

Safety considerations

Incomplete protection against CMV infectionOff-target immune reactionsCytokine release syndromeInjection site reactionsSystemic inflammatory response
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

pp65 antigenemiaCMV-specific T-cell responseTumor pp65 expression

Beyond the preview

Go deeper on 65 kDa phosphoprotein (pp65).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 65 kDa phosphoprotein (pp65).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call